MDGL Q2 2019 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$28,000

Operating Income

-$23M

Net Income

-$20M

EPS (Diluted)

$-1.28

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$470M

Total Liabilities

$13M

Stockholders' Equity

$457M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$28,000	-$24,000	-16.7%
Operating Income	-$23M	-$8M	-190.1%
Net Income	-$20M	-$6M	-204.9%